NEW YORK, March 19 - Deltagen will be collaborating with researchers at Mount Sinai Hospital in Toronto in an international consortium to conduct functional analysis of the mouse genome, the company said Monday.
The researchers at Mount Sinai's Center for Modeling Human Disease will work to study the functions of the mouse genome, as well as develop tools for functional analysis. The CMHD will generate mouse models using chemical mutagenesis by ethylnitrosourea, gene trap mutagenesis, and targeted deletion mutagenesis, then will test and analyze the models for gene-related physiological changes.
Deltagen of Menlo Park, Calif., will contribute its mouse technology and will have the right to commercialize any further developments generated as a result of the research.
"As a leader in discovering and characterizing gene functions in mammalian models, this will provide us with access to additional gene function data and intellectual property that can complement and expand our products and intellectual property portfolio," said Deltagen CEO William Matthews in a statement. "The combined forces of this consortium will also provide us with new opportunities to advance our own drug discovery efforts."
In the past year, Deltagen has sold subscriptions to its database of mammalian gene function information, called DeltaBase, to GlaxoSmithKline and Pfizer. Deltagen charged Pfizer $15 million for a three-year subscription and said it signed a similar deal with GlaxoSmithKline.